📌 𝐖𝐚𝐭𝐜𝐡 𝐋𝐈𝐕𝐄 𝐢𝐧 𝟏 𝐇𝐎𝐔𝐑! ➡️ ms.spr.ly/6010S7XQA Your T1D strategy is about to evolve. We're tackling the 40% of patients who develop CKD despite current therapy. Not to be missed! #Endocrinology #CME

CATALYST study found hypercortisolism in 24% of patients tested. They had ⬆️ CVD, ⬆️ medication burden, features beyond obesity, and, despite use of GLP1s, SGLT2s, or tirzepatide, their T2D remained poorly controlled. 𝐈𝐂𝐘𝐌𝐈 - 𝐖𝐚𝐭𝐜𝐡 𝐍𝐨𝐰! 📌 ms.spr.ly/6013s1QX5

We know there's often a delay in diagnosing PAH - closing that gap can be life-changing for patients. It starts with early recognition and rapid referral to a specialist center. Discover key insights on diagnosis and referral practices from our expert-led discussion ▶️

⁉️ POP QUIZ 𝐖𝐡𝐚𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐫𝐨𝐥𝐞 𝐨𝐟 𝐀𝐩𝐨𝐂-𝐈𝐈𝐈 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 𝐢𝐧 𝐭𝐫𝐞𝐚𝐭𝐢𝐧𝐠 𝐡𝐲𝐩𝐞𝐫𝐭𝐫𝐢𝐠𝐥𝐲𝐜𝐞𝐫𝐢𝐝𝐞𝐦𝐢𝐚? Access the Latest Clinical Advances for SHTG 👉 ms.spr.ly/6018qIn0Y

ICYMI! For the first time since 1993, a new therapy for kidney disease in type 1 diabetes may be on the horizon. We explore the FINE-ONE trial and how it could change the treatment landscape ➡️ x.com/Medscape/statu… #Diabetes #CME

𝐖𝐀𝐓𝐂𝐇 𝐋𝐈𝐕𝐄 𝐢𝐧 𝟏 𝐇𝐎𝐔𝐑! 🎉 ms.spr.ly/6010s6DX6 The Sugar Queens are taking YOUR most pressing questions about prescribing CGM for patients w/ diabetes also taking GLP-1 RAs. Don't miss this! 💕 Davida Kruger Jennifer Goldman

What's next for kidney protection in type 1 diabetes? Current guidelines leave patients with high residual risk for CKD. Experts discuss how the non-steroidal MRA Finerenone, being tested in the FINE-ONE trial, could become a new pillar of care. Watch the full discussion now ➡️

FCS patients have lifelong severe HTG (>1000 mg/dL), while multifactorial HTG is episodic and influenced by 2° factors. The dyslipidemic, hepatic, and pancreatic complications of FCS are serious, requiring frequent hospitalizations. Learn the latest! 📌 ms.spr.ly/6017SdPHP

A breakthrough study for type 1 diabetes ❗ About 25-30% of people with T1D will develop chronic kidney disease. We dive into the groundbreaking FINE-ONE trial, which uses a novel "bridging biomarker" concept to test a potential new therapy for this population. Hear what this

Are you confident in identifying early-stage Type 1 Diabetes? Our new CME activity, "Detecting and Managing Early-Stage Type 1 Diabetes in Clinical Practice," explores the crucial questions: who, what, when, why, and how to effectively screen and stage T1D. Enhance your skills

ICYMI! Are you screening the right patients for MASLD? Our experts discuss why individuals with type 2 diabetes are a critical population to screen, as 1 in 5 may already have clinically significant fibrosis. Learn the latest screening guidelines now ➡️ x.com/Medscape/statu…

⬇️ TELL US BELOW: 𝐖𝐡𝐢𝐜𝐡 𝐨𝐟 𝐭𝐡𝐞 𝐟𝐨𝐥𝐥𝐨𝐰𝐢𝐧𝐠 𝐢𝐬 𝐚𝐧 𝐅𝐃𝐀-𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜𝐚𝐥𝐥𝐲 𝐟𝐨𝐫 𝐟𝐚𝐦𝐢𝐥𝐢𝐚𝐥 𝐜𝐡𝐲𝐥𝐨𝐦𝐢𝐜𝐫𝐨𝐧𝐞𝐦𝐢𝐚 𝐬𝐲𝐧𝐝𝐫𝐨𝐦𝐞 (𝐅𝐂𝐒)? Learn More Here 👉 ms.spr.ly/6017qInC7

The diagnostic journey for NTRK+ thyroid cancer can be tough and frustrating. 💔 But finding this rare biomarker changes everything. Our latest CME activity explores the huge impact of precision care. Learn why testing is key & how new therapies are making a real difference for

CATALYST study found hypercortisolism in 24% of patients tested. They had ⬆️ CVD, ⬆️ medication burden, features beyond obesity, and, despite use of GLP1s, SGLT2s, or tirzepatide, their T2D remained poorly controlled. 𝐈𝐂𝐘𝐌𝐈 - 𝐖𝐚𝐭𝐜𝐡 𝐍𝐨𝐰! 📌 ms.spr.ly/6015sGBnH

Turn the latest research into real-world results. In this CME activity, we provide a practical roadmap for applying new treatments for patients with heart and kidney conditions. Build your confidence and improve patient care today ▶️ medscape.org/viewarticle/10… #CME

What's the first step in liver fibrosis screening? Current guidelines are changing how we risk-stratify patients. Experts simplify the process for primary care, starting with the accessible FIB-4 score to identify patients who need further non-invasive testing. Watch the full

Acute pancreatitis risk rises significantly when TG >1000 mg/dL; becomes severe >2000 mg/dL. Free fatty acids from TG lipolysis in pancreatic capillaries cause endothelial damage, ischemia, and inflammation, leading to pancreatitis. Learn the latest! 📌 ms.spr.ly/6014SdPP4

"GLP-1s are phenomenal!" Davida Kruger explains why they aren't enough for patients with T2D. They need a CGM on board, too! 👑 Watch The Sugar Queens to see how CGM = important lifestyle changes. ➡️ ms.spr.ly/6017sVvD9

“You cannot get this level of data and this level of information or power from finger sticks. It's impossible.” Jennifer Goldman explains the "empowerment and efficacy" that comes from CGM + GLP-1 RAs working hand-in-hand. 👑 Watch The Sugar Queens ➡️ ms.spr.ly/6012sVvam

A new era for MASH management! ❗ With new pharmacologic treatments available, correctly identifying patients with F2/F3 fibrosis is crucial. We dive into how to use non-invasive tests (NITs) to select candidates for therapy and avoid unnecessary biopsies. Hear what this could